Amphastar Pharmaceuticals Cost of Goods Sold 2012-2024 | AMPH

Amphastar Pharmaceuticals cost of goods sold from 2012 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
Amphastar Pharmaceuticals Annual Cost of Goods Sold
(Millions of US $)
2023 $293
2022 $250
2021 $238
2020 $207
2019 $190
2018 $188
2017 $150
2016 $151
2015 $174
2014 $159
2013 $143
2012 $114
2011 $90
2009 $36
Amphastar Pharmaceuticals Quarterly Cost of Goods Sold
(Millions of US $)
2024-09-30 $89
2024-06-30 $87
2024-03-31 $82
2023-12-31 $82
2023-09-30 $72
2023-06-30 $73
2023-03-31 $66
2022-12-31 $64
2022-09-30 $62
2022-06-30 $60
2022-03-31 $65
2021-12-31 $65
2021-09-30 $61
2021-06-30 $54
2021-03-31 $58
2020-12-31 $59
2020-09-30 $47
2020-06-30 $53
2020-03-31 $48
2019-12-31 $50
2019-09-30 $45
2019-06-30 $47
2019-03-31 $49
2018-12-31 $55
2018-09-30 $46
2018-06-30 $45
2018-03-31 $41
2017-12-31 $40
2017-09-30 $37
2017-06-30 $38
2017-03-31 $34
2016-12-31 $44
2016-09-30 $37
2016-06-30 $36
2016-03-31 $34
2015-12-31 $44
2015-09-30 $46
2015-06-30 $41
2015-03-31 $44
2014-12-31 $44
2014-09-30 $48
2014-06-30 $34
2014-03-31 $33
2013-12-31 $35
2013-09-30 $39
2013-06-30 $35
2013-03-31 $33
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.097B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00